Sg Americas Securities, LLC Kinnate Biopharma Inc. Transaction History

Sg Americas Securities, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$2.24 - $2.66 $46,634 - $55,378	20,819 New	20,819 $55,000
Q1 2023 Apr 28, 2023	BUY	$3.46 - $7.98 $10,359 - $23,892	2,994 Added 28.69%	13,429 $84,000
Q4 2022 Feb 02, 2023	SELL	$5.26 - $12.19 $7,779 - $18,029	-1,479 Reduced 12.41%	10,435 $64,000
Q3 2022 Oct 31, 2022	BUY	$9.86 - $15.76 $2,681 - $4,286	272 Added 2.34%	11,914 $142,000
Q2 2022 Jul 29, 2022	BUY	$7.43 - $13.0 $86,500 - $151,346	11,642 New	11,642 $147,000
Q1 2022 Apr 29, 2022	SELL	$7.73 - $17.99 $59,575 - $138,648	-7,707 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$16.5 - $25.48 $126,687 - $195,635	-7,678 Reduced 49.91%	7,707 $137,000
Q3 2021 Nov 01, 2021	BUY	$17.81 - $24.87 $274,006 - $382,624	15,385 New	15,385 $354,000
Q1 2021 May 13, 2021	SELL	$26.99 - $40.0 $361,666 - $536,000	-13,400 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$36.35 - $45.25 $487,090 - $606,350	13,400 New	13,400 $533,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.